SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as discussions revolve around Trump's recent actions, including terminating trade negotiations with Canada following a controversial ad, and community members are debating the implications of White House renovations.  Political affiliations and opinions on Trump's leadership continue to fuel conversations around the stock.  The stock price and potential financial gains also remain a point of interest.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members emphasizing its potential for significant gains and associating it with a 'winning lifestyle.' Many are highlighting its availability on Phantom Wallet and encouraging others to buy and hold. The community sentiment is largely bullish, with recurring themes of 'moonshots' and 'big bags.'

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amidst speculation and conflicting reports about potential U.S. government investment in quantum computing firms, sparking volatility and heightened trading volume. The community is debating the validity of the news and the long-term potential of quantum technology, with bulls anticipating significant gains while bears caution about overvaluation. Discussions also involve comparisons to competitors and the broader implications of government support for the sector.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending amid discussions around its AI infrastructure potential, particularly following a recent partnership with Palantir. Community members are debating the company's valuation, debt levels, and future prospects in the AI-driven data center market, with some expressing optimism about long-term growth and potential for significant share price appreciation.

Aptera Motors Corp. is an automotive technology company focused on the development, production, and distribution of energy-efficient, solar-powered, battery-electric vehicles. Its flagship product, the Aptera, is a three-wheeled, two-seat solar vehicle designed to reduce reliance on traditional charging by utilizing integrated solar panels. The company was founded by Steve Fambro and Chris Anthony and is headquartered in San Diego, CA.

Aptera Motors Corp - Ordinary Shares - Class B

Aptera Motors Corp

Aptera Motors ($SEV) is trending as the community debates its valuation and potential following a Fox News segment and recent direct listing. Discussion centers on the significance of pre-orders versus actual revenue, with bulls emphasizing the company's innovative solar EV technology and future growth potential, while bears point to the lack of current sales and a possible offering. Additionally, some traders are monitoring AWX, another low float ticker, for a potential surge.

Titcoin is a meme coin with the breast technology in crypto. Launched fairly using the PumpFun platform $titcoin is an organic meme coin that is community driven. Supply from the team was locked and since launched using PumpFun the liquidity is locked. Titcoin is about female empowerment and celebrating women's bodies and shapes. Titcoin is built on the Solana Blockchain and the liquidity is through the Raydium platform.

titcoin

Titcoin's (TITCOIN) recent price action and trending status have sparked lively discussions among crypto enthusiasts. Community members are actively trading the meme coin, while also speculating about its potential and longevity in the volatile crypto market. The coin's provocative name is also a key talking point.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders react to natural gas price movements and storage data, with community members actively discussing weather forecasts and LNG exports' impact. Talk centers on whether recent price increases can be sustained amidst ongoing market volatility. Some traders are closely watching technical indicators for potential breakout or reversal signals.

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

LENZ Therapeutics is trending due to the commercial availability of its VIZZ eye drops for presbyopia, sparking discussions about the drug's efficacy and potential to disrupt the market, with some community members comparing it favorably to existing treatments and analysts projecting strong launch potential; some investors are also encouraged by analysts' buy ratings and price target updates. The stock's movement is also influenced by broader sector trends and speculation about potential catalysts and upcoming financial results.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

LI is trending as community members discuss its potential as a stealth accumulator, with some pointing to improving breadth and catalysts that may trigger a rapid move. Bullish sentiment is fueled by sector strength and quiet buy-side interest, while others debate the company's delivery numbers and competitive positioning against peers like NIO. Some traders are closely monitoring news flow related to potential news regarding the i6 model and its impact on sales and momentum.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Airlines is trending due to a recent IT outage that grounded flights and disrupted travel, sparking community frustration and conversation around airline reliability. This incident compounds concerns following a slashed 2025 profit outlook, leading to discussions about the airline's financial health amid rising fuel costs and operational challenges. Despite some defending the airline's solid numbers and long-term potential, the events have intensified scrutiny of ALK's performance in the competitive airline sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock?

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -26.87% and -32.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Latest Ratings for EYPT
 DateFirmActionFromTo Nov 2021HC Wainwright & Co.MaintainsBuy May 2021HC Wainwright & Co.MaintainsBuy Jan 2021Cantor FitzgeraldInitiates Coverage OnOverweight
 View More...

Shares of 4D Molecular Therapeutics Inc. (FDMT) plummeted over 35% to $17.30 by Wednesday afternoon, marking it as the top loser among U.S. stocks. Surprisingly, retail traders remain highly bullish on the stock, with Stocktwits sentiment extremely bullish (85/100) amid extremely high message volumes (95/100).<figure class="image"><img style="aspect-ratio:1308/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_Sentiment_Meter_On_Jul_17_5f2f85024d.png" alt="FDMT Stocktwits Sentiment Meter On Jul 17" width="1308" height="308"><figcaption>FDMT Stocktwits Sentiment Meter On Jul 17</figcaption></figure>Initially, FDMT shares climbed following the release of encouraging mid-stage clinical study results for its 4D-150 gene therapy, aimed at treating wet age-related macular degeneration (wAMD), a chronic eye disorder that leads to blurred vision or blind spots in central vision.However, the broader market turned its focus to various downside risks, including safety concerns raised by RBC Capital. While the firm maintains 4D-150 is "best in class," it flagged a "safety blip" – one case of inflammation in a patient with a history of syphilis, Investing.com <a href="https://in.investing.com/news/stock-market-news/4d-molecular-therapeutics-tumbles-following-midstage-clinical-study-results-432SI-4316187">reported</a>. BMO Capital lowering the price target further may have added to the pressure.Despite the sell-off, retail investors on Stocktwits seem to view Wednesday’s crash as a buying opportunity. One user noted that 4D’s peers, Ocular Therapeutix Inc. (OCUL), Adverum Biotechnologies Inc (ADVM) and EyePoint Pharmaceuticals Inc. (EYPT), “are taking it on the chin today.”“Obviously, Nasdaq taking it hard today as well. &nbsp;Perhaps, just a general opinion of overvaluation and market fatigue? &nbsp;Very odd stock movement to me, I do expect it will reverse soon,” said Stocktwits user ‘<a href="https://stocktwits.com/ehschunk/message/579821570">ehschunk</a>’.<figure class="image"><img style="aspect-ratio:1318/454;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_stocktwits_comment_Jul_17_88b7f49b68.png" alt="Stocktwits user ehschunk's post on FDMT stream" width="1318" height="454"><figcaption>Stocktwits user ehschunk's post on FDMT stream</figcaption></figure>The overall market sentiment didn’t help, as U.S. stocks pulled back from their all-time highs on Wednesday, impacted by falling chip and tech stocks, though the Dow Jones managed its sixth consecutive day of gains.FDMT shares are down over 19% year-to-date, contrasting with OCUL’s impressive 65% rise. EYPT has had an even tougher year, losing 57% so far, while ADVM has lost only 0.18%.However, FDMT’s consistent performance in beating EPS estimates for the past four quarters provides some relief and hope for a rebound among its retail investors.

Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics

Wall Street’s Top Loser Today Remains In Retail’s Good Books

Equity

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics on promising clinical study results

Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.
read more...

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O...

EyePoint Pharmaceuticals (EYPT, $20.27) RSI Indicator left the oversold zone on April 01, 2024

This is a signal that EYPT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

EyePoint Pharmaceuticals (EYPT, $20.27) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that EYPT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EYPT
EyePoint Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EYPT News

EYPTEyePoint Pharmaceuticals Inc